Non-Small-Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia by Sutandyo, Noorwati & Suratman, Eddy
291
ORIGINAL ARTICLE
Acta Med Indones - Indones J Intern Med • Vol 50 • Number 4 • October 2018
Non-Small Cell Lung Carcinoma in Women: A Retrospective 
Cohort Study in Indonesia
Noorwati Sutandyo1, Eddy Suratman2
1 Department of Hematology and Medical Oncology, Dharmais National Cancer Centre Hospital, Jakarta, Indonesia.
2 Departement of Pulmonology, Dharmais National Cancer Centre Hospital, Jakarta, Indonesia.
Corresponding author:
Noorwati Sutandyo, MD., PhD., FINASIM. Department of Hematology and Medical Oncology, Dharmais National 
Cancer Centre Hospital. Jl. Let.Jend. S. Parman Kav. 84-86, Slipi, Jakarta 11420, Indonesia. email: noorwatis3@yahoo.com.
ABSTRAK
Latar belakang: kanker paru merupakan kanker terbanyak di dunia baik pada pria maupun wanita. Kanker 
paru pada wanita berbeda dengan pada pria dalam berbagai aspek. Peningkatan trend kanker paru pada wanita 
terjadi di Indonesia. Studi ini dilakukan untuk melihat karakteristik dan kesintasan kanker paru karsinoma bukan 
sel kecil pada wanita di RS Pusat Kanker Nasional Dharmais. Metode: penelitian ini merupakan studi kohort 
retrospektif mengenai karateristik pasien wanita dengan kanker paru karsinoma bukan sel kecil dengan mengambil 
data sekunder mulai Januari 2005 sampai Desember 2015. Analisis kesintasan menggunakan kurva Kaplan-Meier. 
Faktor-faktor prognostik independen dianalisis dengan menggunakan model regresi Cox risiko proporsional dengan 
hazard ratio (HR) dan interval kepercayaan (CI) sebesar 95%. Hasil: dari studi didapatkan karsinoma paru bukan 
sel kecil sebanyak 956 kasus, 256 diantaranya adalah wanita. Rata-rata usia yang didapatkan adalah 56,9 (11,87) 
tahun. Riwayat merokok dijumpai pada 21 pasien (7,8%). Jenis histologi terbanyak adalah adenokarsinoma 
(91,1%), dan 261 pasien (98,0%) berada pada stadium lanjut (III-IV). Median kesintasan sedikit lebih panjang 
pada perempuan dibandingkan dengan laki-laki (14.9 bulan berbanding 12.2 bulan; log-rank p= 0,055). Faktor 
prognostik signifikan terhadap kesintasan adalah usia yang lebih dari 50 tahun (HR=0,681; 95% CI=0,467 – 
0,992; p=0,045) dan mutasi eGFR positif (HR=0,393; 95% CI=0,251–0,615; p<0,001). Kesimpulan: dua puluh 
delapan persen kasus karsinoma paru bukan sel kecil diderita oleh perempuan. Sebagian besar tidak merokok, 
memiliki histopatologi adenokarsinoma, dan mutasi eGFR. Kesintasan ditemukan lebih baik pada pasien wanita 
dibandingkan dengan laki-laki. Faktor prognostik positif terhadap kesintasan pada pasien wanita dengan kanker 
paru adalah usia lebih dari 50 tahun dan adanya mutasi eGFR.
Kata kunci: karsinoma paru bukan sel kecil, wanita, karakteristik, mutasi eGFR, kesintasan.
ABSTRACT
Background: the increasing incidence of lung cancer in female patients has been observed in Indonesia. Lung 
cancer in female might have different biology process than male, but it has never been evaluated in Indonesia. This 
study aimed to know characteristics and survival of female patients with non-small-cell lung carcinoma (NSCLC) 
in Dharmais National Cancer Centre Hospital. Methods: a retrospective cohort study was performed among 
NSCLC female patients in Dharmais National Cancer Centre Hospital between January 2005 and December 
2015. Survival analysis was done using the Kaplan-Meir estimation curve with proportional assumption test. 
Independent prognostic factors were analyzed using the Cox proportional hazard model with a hazard ratio (HR) 
and its 95% confidence interval (CI). Results: a total of 956 NSCLC cases were retrieved during the study; 268 
(28.0%) were female patients. Mean of age in female patients was 56.9 (11.87) years old. Among female patients, 
21 (7.8%) were smokers, 244 (91.1%) had adenocarcinoma subtype, and 261 (98.0%) were in advanced stage 
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(III-IV). Median survival was slightly longer in female than male patients (14.9 months vs. 12.2 months; log-rank 
p=0.055). Significant prognostic factors for survival were older age (>50 y.o) (HR = 0.681; 95% CI = 0.467 – 0.992; 
p= 0.045) and positive eGFR mutation (HR = 0.393; 95% CI = 0.251 – 0.615; p<0.001). Conclusion: female 
patients contributed to about 28% of all NSCLC cases. They were mostly non-smokers, had more adenocarcinoma 
histopathology and eGFR mutation. Survival tended to be longer in female than male patients. Age over 50 years 
and the presence of eGFR mutation were good prognostic factors to survival in female lung cancer patients.
Keywords: non-small cell lung carcinoma, female, characteristics, eGFR mutation, overall survival.
INTRODUCTION
Lung cancer is the most common cancer 
diagnosed in the last decade. In 2012, there were 
1.2 million new cases of lung cancer in male and 
500,000 in female.1 In  2017, there were 222,500 
new cases and 155,870 deaths from lung cancer.2 
Historically, lung cancer was more common in 
male than in female, but this gender proportion 
has changed largely during the last two decades; 
lung cancer incidence is decreasing in male 
but continue to increase in female.3 However, 
mortality rate is lower in female than male lung 
cancer patients. The 5-year survival rate is 21% 
for female and 15% for male patients.4
The increasing incidence of lung cancer in 
female was thought to be caused by increasing 
number of female passive smokers, particularly 
in developed countries. However, lung cancer 
among female may behave differently than 
male. Female patients tend to be younger, non-
smokers, have more adenocarcinoma subtypes 
and longer survival rates than male patients.5 
Several factors have been associated with lung 
cancer in female, i.e. environmental exposures, 
genetic predisposition, hormonal factors and 
viral infection.6
Lung cancer in female has not been well 
studied in Indonesia. Therefore, this was the first 
study aimed to know characteristics and survival 
of non-small cell lung cancer (NSCLC) in female 
patients in Indonesia.
METHODS
A retrospective cohort study was performed 
in Dharmais National Cancer Centre Hospital 
Jakarta on NSCLC patients between January 2005 
and December 2015. Data were obtained from 
patients’ medical records which was correlated 
to other study on “characteristics at risk factors in 
lung cancer”. Inclusion criteria were adult patients 
aged more than 18 years old and was diagnosed 
as NSCLC based on histopathology or cytology 
assessment. Speciments for NSCLC diagnosis 
were taken from lung tissues, bronchial swabs, 
lymph node aspirate or pleural effusion fluid. 
Clinical data from each patient were collected and 
included age, smoking status, histopathology type, 
staging and survival. Histopathology subtypes 
were grouped into adenocarcinoma, squamous 
cell carcinoma (SCC), and large cell carcinoma. 
The presence of mutation of epidermal growth 
factor receptor (EGFR) was also recorded. 
This study had been approved by the Ethical 
Committee for Medical Research, Dharmais 
Cancer Hospital, Jakarta with a reference number 
031/KEPK/V/2016.
Statistical Analysis
Clinical data of female and male patients 
were compared and presented descriptively. 
Categorical data were expressed as frequency 
and percentage, while continuous data were 
presented as mean and standard deviation for 
normally distributed data or median and range 
for skewed data. Association between categorical 
variables was analyzed using the Chi-square 
test with calculated odds ratio (OR) and 95% 
confidence interval (CI). Mean difference was 
analyzed using the student t test. A p value 
of <0.05 was considered significant. Overall 
survival (OS) was calculated from the patient’s 
initial diagnosis to the last visit during follow-up 
(December 31st, 2016) or death. Survival analysis 
was performed using Kaplan-Meier curve 
estimation with the proportional assumption test. 
A log-rank p of less than 0.05 was considered 
significant. Cox proportional hazard analysis 
were performed to identify significant prognostic 
factors to survival after adjusting for potential 
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significant confounders. Hazard ratios (HRs) and 
95% confidence intervals (CI) were calculated for 
each variable. In the final adjusted multivariable 
Cox proportional hazard models, five potential 
confounding variables on the overall survival 
were evaluated, i.e. age, smoking history, the 
presence of distant metastasis, histopathological 
subtypes, and EGFR mutation. Statistical 
analysis were done using SPSS version 17.0 
software.
RESULTS
A total of 956 patients met the inclusion 
criteria during the study period; 268 (28.0%) of 
them were female patients. The mean of age in 
female patients was 56.9 (11.87) years, ranging 
from 24 to 91 years old. The peak age interval 
was between 51 and 60 years old (38.1%). Mean 
of age was slightly lower in female compare to 
male patients (56.9 vs. 58.2 years; p=0.117). 
Twenty-one (7.8%) of female patients were 
smokers, with a frequency between 3 and 48 
cigarettes per day. Female patients significantly 
smoked less compared to male patients, had 
higher percentage of adenocarcinoma and EGFR 
mutation in histopathology, and diagnosed in 
advanced stage (Table 1). Cases of lung cancer 
tended to increase from 2005 to 2015 (Figure 1).
Female patients had increased odds ratio 
to develop adenocarcinoma (OR=5.587; 95% 
CI=3.572–8.470), stage IV B (OR=1.462; 95% 
CI=1.101-1.942) and EGFR mutation (OR=2.015; 
95% CI=1.426–2.848) compared to male patients. 
On the contrary, female had decreased odds ratio 
Table 1. Comparison between female and male patients with NSCLC in Dharmais National Cancer Centre Hospital from 
January 2005 to December 2015
Charactersitcs Female (n=268) Male (n=688) Total p*
Age, n (%)
 - > 50 years old 201 (75.0) 524 (76.2) 725 (75.8) 0.706
 - < 50 years old 67 (25.0) 164 (23.8) 231 (24.2)
Smoking
 - Yes 21 (7.8) 272 (39.5) 293 (30.6) <0.001
 - No 247 (92.2) 416 (60.5) 663 (69.4)
Brinkman Index
 - Not smoking 247 (92.2) 416 (60.5) 663 (69.4) <0.001
 - Mild 8 (3.0) 21 (3.1) 29 (3.0)
 - Moderate 5 (1.9) 127 (18.5) 132 (13.8)
 - Heavy 8 (3.0) 124 (18.0) 132 (13.8)
Histopathology
 - Adenocarcinoma 244 (91.1) 444 (64.5) 688 (72.0) <0.001
 - Squamous cell 17 (6.3) 221 (32.1) 238 (24.9)
 - Large cell 7 (2.6) 23 (3.4) 30 (3.1)
Disease stage 
 - I-II 7 (2.6) 26 (3.7) 33 (3.4) 0.119
 - IIIA 21 (7.8) 69 (10.0) 90 (9.4)
 - IIIB 30 (11.2) 117 (17.0) 147 (15.4)
 - IVA 62 (23.1) 159 (23.1) 221 (23.1)
 - IVB 148 (55.2) 317 (46.1) 465 (48.6)
EGFR mutation
 - Yes 69 (25.7) 101 (14.7) 170 (17.8) <0.001
 - No 199 (74.3) 587 (85.3) 786 (82.2)
Figure 1. Incidence of lung cancer in female patients in 
Dharmais National Cancer Centre Hospital, 2005-2015.
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of smoking (OR=0.130; 95% CI = 0.081 – 0.208). 
Among patients with squamous cell carcinoma 
subtype, 5/17 (29.4%) were smokers, while in 
other histopathological subtypes, 16/251 (6.4%) 
were smokers; smoking was associated with 
higher odds ratio to develop SCC (OR=6.120; 
95% CI =1.919 – 19.526; p = 0.002).
Survival Analysis
 Females had a slightly longer overall 
survival than male patients (median 14.9 vs. 
12.2 months, log-rank p = 0.055, Figure 2). 
Median survival was longer in patients aged >50 
years than patients aged <50 years (15.3 vs. 13.6 
months; log-rank p = 0.043; Figure 3). Patients 
with eGFR mutation had longer median survival 
time than patients without eGFR mutation (27.7 
vs. 12.2 months; log-rank p <0.001; Figure 4). 
Older age (>50 years old) and positive eGFR 
mutation was significantly associated with lower 
mortality rate (Table 2). Cox proportional hazard 
model showed that age >50 years old and positive 
eGFR mutation were significant prognostic 
factors of survival in female NSCLC patients 
(Table 3).
DISCUSSION
This study was the first evaluation on 
NSCLC female patients in Indonesia. In this 
report, we found that females comprised 28% 
of lung cancer patients in Dharmais National 
Figure 2. Kaplan Meier curves showing survival difference 
between male and female lung cancer patients in Dharmais 
National Cancer Centre Hospital, January 2005 – December 
2015
Table 2. Factors associated with mortality in NSCLC female patients (n=268)
Characteristic Died (n=121) Alive (n=147) OR (95% CI) p*
Age group, n (%)
 - > 50 years 78 (38.8) 123 (61.2) 0.354 (0.199– 0.629) <0.001
 - < 50 years 43 (64.2) 24 (35.8)
Smoking, n (%)
 - Yes 9 (42.9) 12 (57.1) 0.904 (0.368–2.223) 0.826
 - No 112 (45.3) 135 (54.7)
Histopathology, n (%)
 - SCC 10 (58.8) 7 (41.2) 0.555 (0.205–1.505) 0.242
 - Others 111 (44.2) 140 (55.8)
Distant metastasis, n (%)
 - Yes 73 (48.7) 77 (51.3) 1.383 (0.849–2.251) 0.192
 - No 48 (40.7) 70 (59.3)
EGFR mutation, n (%)
 - Yes 25 (36.2) 44 (63.8) 0.610 (0.347–1.072) 0.084
 - No 96 (48.2) 103 (51.8)
Cancer Centre Hospital. However, the annual 
incidence was increasing from 2005 to 2015; if 
the trend continues, we may expect more female 
patients in the future. A large lung cancer registry 
in Poland during 1995-1998 found that female 
patients constitute 14.0% of all lung cancer cases 
(both NSCLC and SCLC cases).7 A study in 
Pakistan reported an incidence rate of 11.8% of 
female patients from 830 cases of lung cancers.8 
In this study, mean of age (56.9 years old) 
was slightly lower than a US study involving 
485 NSCLC female patients with a mean age 
of 60.1 years old.9 It was also lower than the 
Poland lung cancer registry (60.0 years old).7 As 
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comparison, the Pakistani study found a mean 
age of 57.5 years old, which were significantly 
lower than the male patients (60.1 years old).8 
In a recent study from China, the mean age was 
59.7 years old for female and 62.7 years old for 
male patients.10 Most of female patients (75.0%) 
were diagnosed at the age of more than 50 years 
old. This is comparable with the data from the 
Poland lung cancer registry (76.7%).7
Adenocarcinoma was the predominant 
subtype in female patients (91.1%), while SCC 
was only found in a small percentage (6.3%). 
Similar pattern was also reported in China, which 
showed that adenocarcinoma was found in 86.9%, 
while SCC was only 5.8% of female patients.10
Mutation of the EGFR gene was higher in 
female than male patients. This finding is also 
observed in other Asian studies. For example, 
the study from China found that EGFR mutation 
was present in 66% of female patients with 
adenocarcinoma subtype.10 EGFR mutation is 
lower in European population. New report from 
Spain found EGFR mutation in 34.4% of 1,775 
NSCLC female patients.11 It is generally accepted 
currently that EGFR mutations are more common 
in female patients, in non-smokers and in those 
with adenocarcinoma histology.12,13
In our study, only a small proportion of female 
patients were smokers. Male sex was associated 
with 7.6 times higher odds ratio of being smoker 
than female patients. A study in Japan found that 
less than 10% of female lung cancer patients 
had smoking history, either current or former 
smoker.14 The study in China even found less 
proportion; only 2.7% of the female patients were 
smokers.10 Data from Singapore showed that 
79.4% of female patients with advanced NSCLC 
were non-smokers.15 Apparently, female lung 
cancer patients who reported tobacco smoking 
were lower in Asia than the Western countries. 
Recent meta-analyses showed that the prevalence 
of smoking worldwide was 11.7 – 97.5% in 
male and 5.9 – 67.7% in female.16 Furthermore, 
unlike in males, current data did not support the 
hypothesis that smoking increases lung cancer 
risk in female.17 However, recent result from 
a prospective cohort study in UK found that 
moderate and heavy smokers among females 
have a higher risk of lung cancer than male.18
The association between smoking and lung 
cancer was stronger for small cell carcinoma, 
SCC, and large cell carcinoma than for 
adenocarcinoma.19 In this current study, smoking 
was associated with 6.1 times higher risk of 
having SCC subtype in female patients. A Japan 
study found that lung cancer risk was 10- to 20-
Figure 3. Kaplan Meier curves showing survival difference 
female lung cancer patients aged >50 years and  < 50 years 
old in Dharmais National Cancer Centre Hospital, January 
2005 – December 2015
Figure 4. Kaplan Meier curves showing survival difference 
between female lung cancer patients with and without EGFR 
mutation in Dharmais Cancer Hospital, January 2005 – 
December 2015
Table 3. Cox proportional hazard model to predict survival 
in NSCLC female patients (n=268)








-0.934 0.229 0.393 (0.251–0.615) <0.001
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fold higher for SCC and small cell carcinoma but 
only 2- to 3-fold higher for adenocarcinoma in 
male and female patients.14 Recent study showed 
that both in males and females, adenocarcinoma 
was more frequently found in non-smokers than 
in former or current smokers.20
The finding that more than 90% of female 
patients with adenocarcinoma in this study were 
non-smokers suggested that other factors may 
contribute to the pathogenesis of this subtype 
of lung cancer in female. One of the major 
differences between female and male is the 
presence of estrogen and progesterone in female 
that has been suggested to play an important role 
in lung carcinogenesis.21,22 Both type of estrogen 
receptor (ER) a and b are found in NSCLC and 
mediated cell proliferation.23 High expression 
of ER-b1 but low progesterone receptor was 
associated with more aggressive biology and poor 
survival in lung cancer.24 Moreover, aromatase 
enzyme involved on estrogen synthesis is also 
associated with prognosis; lower level of tumor 
aromatase is associated with better survival 
in NSCLC patients.25 Other study showed 
that post-menopausal female who received 
hormone replacement therapy with estrogen and 
progesterone had a higher risk of developing lung 
cancer.26 If the hormonal therapy are used more 
than 10 years, the risk of developing lung cancer 
increase up to 50%.27 Another study reported that 
female patients who received tamoxifen (anti-
estrogen) had a decreased risk of developing 
lung cancer.28
Compared to male patients, our study showed 
that female patients had only slightly longer 
survival (about two months). However, more than 
70% of the patients came with stage IV disease, 
which had poor prognosis. In general, female 
NSCLC patients have longer survival time trend 
than male in all stages and histology type.29
Analysis within the female patients group 
showed that patients aged more than 50 years 
had significantly longer survival than those aged 
less than 50 years. It was also an independent 
prognostic factor after adjusting disease stage 
and histopathology. This finding was similar to 
several studies that observed better survival in 
NSCLC postmemopausal female patients than 
premenopausal ones.30,31 A study by Moore et al.31 
showed that premenopausal women had more 
extensive disease at presentation and increased 
frequency of adenocarcinoma compared to 
postmenopausal women. On multivariate 
analysis, postmenopausal women also had fewer 
lung cancer-related deaths compared to older 
men. This findings may be related to hormonal 
status in women. Sex hormone in female does not 
only correlate to higher incidence in lung cancer, 
but also the outcome.21 However, the underlying 
mechanism to explain the association between 
sex hormone and survival in female patients with 
lung cancer need further studies.
In this study, the presence of EGFR mutation 
was protective against early death as the median 
survival of these patients was more than 2 years 
(27.7 months). Another study in female with 
stage IV NSCLC showed similar result; median 
overall survival was reported to be longer in 
mutated than wild type EGFR (25.6 vs. 16.2 
months, p = 0.20).32 Longer survival found in 
the patients harboring EGFR mutation could 
be due to the administration of EGFR tyrosine 
kinase inhibitor (TKI), as the standard treatment 
in DCH. Recent study from Spain showed that 
NSCLC female patients treated with EGFR TKI 
achieved an OS of 23.0 months.11 Another data 
from Iressa Pan-Asia Study (IPASS) showed 
improved overall survival in patients with EGFR 
mutation-positive NSCLC, whether they receive 
treatment with gefitinib or chemotherapy.33 
However, the underlying mechanism is still 
unknown.
There are several limitations in our study. 
We used data from lung cancer registry and the 
study was not designed as a prospective cohort 
study. However, given the large sample size, 
findings from this registry data may provide clue 
on the incidence and trends of female lung cancer 
patients, particularly NSCLC. Secondly, we did 
not assess menopausal or hormonal status of the 
female patients. The fact that estrogen may affect 
lung carcinogenesis in female deserves further 
study. Similarly, smoking assessment did not 
evaluate the role of environmental tobacco smoke 
or secondhand smoker. As non-smoker patients 
tend to be dominant in Indonesian female, study 
about risk factors for developing lung cancer 
should be elaborated more in the future.
Vol 50 • Number 4 • October 2018              Non-small cell lung carcinoma in women: a retrospective cohort study
297
CONCLUSION
Lung cancer in females is increasing in 
Indonesia. Female patients had different profile 
than males; they were mostly non-smokers, 
had higher percentage of adenocarcinoma 
histopathology, and more EGFR mutation. 
Although most of patients were already in 
advanced stage, overall survival was slightly 
better in female than male patients. Age over 50 
years and the presence of EGFR mutation were 
the positive prognostic factors of survival in 
female lung cancer patients.
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